Cor Vasa 2021, 63(2):272-275 | DOI: 10.33678/cor.2021.032

Beta blockers still relevant

Jaroslav Brotánek
Interní klinika, 1. a 3. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha

Current clinical practice continues to regard beta blockers as very important drugs in a number of indica-tions. What should be taken into account, however, is that individual beta blockers vary and that the diffe-rences between them may infl uence the overall treatment effect or side effects. In choosing the appropriate beta blockers, we should focus on the beta-1 selective agents which have good pharmacokinetic properties and whose effi cacy has been proved by a whole range of clinical trials.

Keywords: Arrhythmias, Beta blockers, Bisoprolol, Coronary artery disease Hypertension, Sympathetic nervous activity

Received: March 3, 2021; Revised: March 3, 2021; Accepted: March 8, 2021; Published: May 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brotánek J. Beta blockers still relevant. Cor Vasa. 2021;63(2):272-275. doi: 10.33678/cor.2021.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J. Současné postavení beta-blokátorů v léčbě hypertenze. Postgrad Med 2010;12:929-934.
    2. Hradec J. Skutečně máme v léčbě hypertenze zatratit beta-blokátory? Kap Kardiol 2010;2:105-109.
    3. Zvýšená aktivita sympatiku se významně promítá do skutečné prognózy nemocných. Med Tribune 2017;13(10):B5.
    4. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993;125:1148-1154. Go to original source... Go to PubMed...
    5. Benetos A, Rudnichi A, Thomas F, et al. Resting Heart Rate: Independent Predictor of Total and CV Mortality in Men and Women. Hypertension 1999;33:44-52. Go to original source... Go to PubMed...
    6. Carnethon MD, Yan L, Greenland P, et al. Heart Rate is Associated with Diabetes Diagnosis and Mortality. Diabetes Care 2008;31:335-339. Go to original source... Go to PubMed...
    7. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821. Go to original source... Go to PubMed...
    8. Widimský J. Současné postavení beta-blokátorů v léčbě hypertenze. Postgrad Med 2010;12:929-934.
    9. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285. Go to original source... Go to PubMed...
    10. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015;33:195-211. Go to original source... Go to PubMed...
    11. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009;3:CD 001841. Go to original source... Go to PubMed...
    12. Law MH, Morfia JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009;338:1665-1683. Go to original source... Go to PubMed...
    13. Neutel JM, Smith DH, Ram CV, et al. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol 1993;72:41-46. Go to original source... Go to PubMed...
    14. Wheeldon NM, MacDonald TM, Prasad N, et al. A double- -blind comparison of bisoprolol and atenolol in patients with essential hypertension. Int J Med 1995;88:865-870.
    15. Tianlun Y, Yinong J, Yuming H, et al. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res 2017;40:79-86. Go to original source... Go to PubMed...
    16. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihyperensive drugs. Am J Hypertens 2007;20:311-318. Go to original source... Go to PubMed...
    17. Mates M, Kala P, Paleček T, et al. Doporučené postupy ESC pro diagnózu a léčbu chronických koronárních syndromů, 2019. Souhrn dokumentu vypracovaný Českou kardiologickou společností. Cor Vasa 2020;62:199-233. Go to original source...
    18. Ošťádal P, Táborský M, Linhart A, et al. Stručný souhrn doporučení pro dlouhodobou péči o nemocné po infarktu myokardu. Cor Vasa 2019;61:e471-e480. Go to original source...
    19. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;42:373-498. Go to original source... Go to PubMed...
    20. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200. Go to original source... Go to PubMed...
    21. CIBIS Investigators and committees. A Randomized Trial of β-Blockade in Heart Failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773. Go to original source... Go to PubMed...
    22. CIBIS-II Investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. Go to original source...
    23. Farmakoterapie chronického srdečního selhání: jak vybrat správný beta-blokátor? Med Tribune 2015;11(3):B8.
    24. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1575. Go to original source... Go to PubMed...
    25. Sova M, Kamasová M, Václavík J, et al. Betablokátory a chronická obstrukční nemoc. Vnitř Lék 2016;62:305-307. Go to PubMed...
    26. Bhatt SP, Wells JM, Kinney GI, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016;71:8-14. Go to original source... Go to PubMed...
    27. Agesen FN, Weeke PE, Hansen PT, et al. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect 2019;7:e00496. Go to original source... Go to PubMed...
    28. Wai B, Kearney LG, Hare DL, et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 2012;11:14. Go to original source... Go to PubMed...
    29. Doležal T. Bisoprolol v terapii srdečního selhání. Remedia 2002;12:219-220.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes